Skip to Content
Merck
  • Identification of differentiation-stage specific markers that define the ex vivo osteoblastic phenotype.

Identification of differentiation-stage specific markers that define the ex vivo osteoblastic phenotype.

Bone (2014-07-02)
Natalie A Twine, Li Chen, Chi N Pang, Marc R Wilkins, Moustapha Kassem
ABSTRACT

The phenotype of osteoblastic (OB) cells in culture is currently defined using a limited number of markers of low sensitivity and specificity. For the clinical use of human skeletal (stromal, mesenchymal) stem cells (hMSC) in therapy, there is also a need to identify a set of gene markers that predict in vivo bone forming capacity. Thus, we used RNA sequencing to examine changes in expression for a set of skeletally-related genes across 8 time points between 0 and 12days of ex vivo OB differentiation of hMSC. We identified 123 genes showing significant temporal expression change. Hierarchical clustering and Pearson's correlation generated 4 groups of genes: early stage differentiation genes (peak expression: 0-24h, n=28) which were enriched for extracellular matrix organisation, e.g. COL1A1, LOX, and SERPINH1; middle stage differentiating genes (peak expression days: 3 and 6, n=20) which were enriched for extracellular matrix/skeletal system development e.g. BMP4, CYP24A1, and TGFBR2; and late stage differentiation genes (peak expression days: 9 and 12, n=27) which were enriched for bone development/osteoblast differentiation, e.g. BMP2 and IGF2. In addition, we identified 13 genes with bimodal temporal expression (2 peaks of expression: days 0 and 12) including VEGFA, PDGFA and FGF2. We examined the specificity of the 123 genes' expression in skeletal tissues and thus propose a set of ex vivo differentiation-stage-specific markers (n=21). In an independent analysis, we identified a subset of genes (n=20, e.g. ELN, COL11A1, BMP4) to predict the bone forming capacity of hMSC and another set (n=20, e.g. IGF2, TGFB2, SMAD3) associated with the ex vivo phenotype of hMSC obtained from osteoporotic patients.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Sigma-Aldrich
1α,25-Dihydroxyvitamin D2 solution, 50 μg/mL in ethanol, 95% (CP)
Pricing and availability is not currently available.
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Pricing and availability is not currently available.
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Pricing and availability is not currently available.
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥99% (HPLC)
Pricing and availability is not currently available.
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Pricing and availability is not currently available.
Supelco
Dexamethasone, VETRANAL®, analytical standard
Pricing and availability is not currently available.
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Supelco
1α,25-Dihydroxyvitamin D2 solution, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Pricing and availability is not currently available.
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥97.0% (HPLC)
Pricing and availability is not currently available.
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Pricing and availability is not currently available.
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Pricing and availability is not currently available.
Sigma-Aldrich
1α,25-Dihydroxyvitamin D2 solution, 100 μg/mL in ethanol, 95% (CP)
Pricing and availability is not currently available.
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Pricing and availability is not currently available.
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Pricing and availability is not currently available.
USP
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
Pricing and availability is not currently available.
Supelco
L-Ascorbic acid, analytical standard
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, ≥98%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, BioUltra, ≥99.5% (RT)
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, tested according to Ph. Eur.
Pricing and availability is not currently available.
Calcitriol, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Supelco
L-Ascorbic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Pricing and availability is not currently available.
Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Pricing and availability is not currently available.